A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

10.1016/j.jtocrr.2022.100416

Saved in:

Bibliographic Details
Main Authors:	Lai, Gillianne GY, Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob JS, Sim, Ngak Leng, Tan, Aaron C, Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie PL, Rohatgi, Neha, Yeong, Joe PS, Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders MJ, Tan, Eng-Huat, Tan, Daniel SW
Other Authors:	DEPARTMENT OF COMPUTER SCIENCE
Format:	Article
Language:	English
Published:	ELSEVIER 2024
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System Lung cancer Epidermal growth factor receptor Immunotherapy Biomarkers CELL LUNG-CANCER TUMOR MUTATIONAL BURDEN OPEN-LABEL PLUS IPILIMUMAB IMMUNE ESCAPE DOCETAXEL PD-L1 PEMBROLIZUMAB BLOCKADE ASSOCIATION
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/248899
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

id	sg-nus-scholar.10635-248899
record_format	dspace
spelling	sg-nus-scholar.10635-2488992024-11-15T08:46:50Z A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC Lai, Gillianne GY Yeo, Jia Chi Jain, Amit Zhou, Siqin Pang, Mengyuan Alvarez, Jacob JS Sim, Ngak Leng Tan, Aaron C Suteja, Lisda Lim, Tze Wei Guo, Yu Amanda Shen, Meixin Saw, Stephanie PL Rohatgi, Neha Yeong, Joe PS Takano, Angela Lim, Kiat Hon Gogna, Apoorva Too, Chow Wei Da Zhuang, Kun Tan, Wan Ling Kanesvaran, Ravindran Ng, Quan Sing Ang, Mei Kim Rajasekaran, Tanujaa Wang, Lanying Toh, Chee Keong Lim, Wan-Teck Tam, Wai Leong Tan, Sze Huey Skanderup, Anders MJ Tan, Eng-Huat Tan, Daniel SW DEPARTMENT OF COMPUTER SCIENCE DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL) CANCER SCIENCE INSTITUTE OF SINGAPORE DUKE-NUS MEDICAL SCHOOL BIOCHEMISTRY Assoc Prof Wan-Teck Darren Lim Science & Technology Life Sciences & Biomedicine Oncology Respiratory System Lung cancer Epidermal growth factor receptor Immunotherapy Biomarkers CELL LUNG-CANCER TUMOR MUTATIONAL BURDEN OPEN-LABEL PLUS IPILIMUMAB IMMUNE ESCAPE DOCETAXEL PD-L1 PEMBROLIZUMAB BLOCKADE ASSOCIATION 10.1016/j.jtocrr.2022.100416 JTO CLINICAL AND RESEARCH REPORTS 3 12 2024-06-14T06:52:04Z 2024-06-14T06:52:04Z 2022-12 2024-06-12T13:48:23Z Article Lai, Gillianne GY, Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob JS, Sim, Ngak Leng, Tan, Aaron C, Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie PL, Rohatgi, Neha, Yeong, Joe PS, Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders MJ, Tan, Eng-Huat, Tan, Daniel SW (2022-12). A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC. JTO CLINICAL AND RESEARCH REPORTS 3 (12). ScholarBank@NUS Repository. https://doi.org/10.1016/j.jtocrr.2022.100416 2666-3643 https://scholarbank.nus.edu.sg/handle/10635/248899 en ELSEVIER Elements
institution	National University of Singapore
building	NUS Library
continent	Asia
country	Singapore Singapore
content_provider	NUS Library
collection	ScholarBank@NUS
language	English
topic	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System Lung cancer Epidermal growth factor receptor Immunotherapy Biomarkers CELL LUNG-CANCER TUMOR MUTATIONAL BURDEN OPEN-LABEL PLUS IPILIMUMAB IMMUNE ESCAPE DOCETAXEL PD-L1 PEMBROLIZUMAB BLOCKADE ASSOCIATION
spellingShingle	Science & Technology Life Sciences & Biomedicine Oncology Respiratory System Lung cancer Epidermal growth factor receptor Immunotherapy Biomarkers CELL LUNG-CANCER TUMOR MUTATIONAL BURDEN OPEN-LABEL PLUS IPILIMUMAB IMMUNE ESCAPE DOCETAXEL PD-L1 PEMBROLIZUMAB BLOCKADE ASSOCIATION Lai, Gillianne GY Yeo, Jia Chi Jain, Amit Zhou, Siqin Pang, Mengyuan Alvarez, Jacob JS Sim, Ngak Leng Tan, Aaron C Suteja, Lisda Lim, Tze Wei Guo, Yu Amanda Shen, Meixin Saw, Stephanie PL Rohatgi, Neha Yeong, Joe PS Takano, Angela Lim, Kiat Hon Gogna, Apoorva Too, Chow Wei Da Zhuang, Kun Tan, Wan Ling Kanesvaran, Ravindran Ng, Quan Sing Ang, Mei Kim Rajasekaran, Tanujaa Wang, Lanying Toh, Chee Keong Lim, Wan-Teck Tam, Wai Leong Tan, Sze Huey Skanderup, Anders MJ Tan, Eng-Huat Tan, Daniel SW A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
description	10.1016/j.jtocrr.2022.100416
author2	DEPARTMENT OF COMPUTER SCIENCE
author_facet	DEPARTMENT OF COMPUTER SCIENCE Lai, Gillianne GY Yeo, Jia Chi Jain, Amit Zhou, Siqin Pang, Mengyuan Alvarez, Jacob JS Sim, Ngak Leng Tan, Aaron C Suteja, Lisda Lim, Tze Wei Guo, Yu Amanda Shen, Meixin Saw, Stephanie PL Rohatgi, Neha Yeong, Joe PS Takano, Angela Lim, Kiat Hon Gogna, Apoorva Too, Chow Wei Da Zhuang, Kun Tan, Wan Ling Kanesvaran, Ravindran Ng, Quan Sing Ang, Mei Kim Rajasekaran, Tanujaa Wang, Lanying Toh, Chee Keong Lim, Wan-Teck Tam, Wai Leong Tan, Sze Huey Skanderup, Anders MJ Tan, Eng-Huat Tan, Daniel SW
format	Article
author	Lai, Gillianne GY Yeo, Jia Chi Jain, Amit Zhou, Siqin Pang, Mengyuan Alvarez, Jacob JS Sim, Ngak Leng Tan, Aaron C Suteja, Lisda Lim, Tze Wei Guo, Yu Amanda Shen, Meixin Saw, Stephanie PL Rohatgi, Neha Yeong, Joe PS Takano, Angela Lim, Kiat Hon Gogna, Apoorva Too, Chow Wei Da Zhuang, Kun Tan, Wan Ling Kanesvaran, Ravindran Ng, Quan Sing Ang, Mei Kim Rajasekaran, Tanujaa Wang, Lanying Toh, Chee Keong Lim, Wan-Teck Tam, Wai Leong Tan, Sze Huey Skanderup, Anders MJ Tan, Eng-Huat Tan, Daniel SW
author_sort	Lai, Gillianne GY
title	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
title_short	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
title_full	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
title_fullStr	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
title_full_unstemmed	A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
title_sort	randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in egfr-mutant nsclc
publisher	ELSEVIER
publishDate	2024
url	https://scholarbank.nus.edu.sg/handle/10635/248899
_version_	1821212991841894400

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

Similar Items